Proprietary AI analyst is now available
- Public Comps
- Impedimed
Impedimed Valuation Multiples
Discover revenue and EBITDA valuation multiples for Impedimed and similar public comparables like Scandinavian ChemoTech, Allurion, Spineguard, Predict and more.
Impedimed Overview
About Impedimed
Impedimed Ltd, together with its subsidiaries, operates in the medical devices space. The company is based in Australia and operates globally, and it generates the majority of its revenue in North America. It is engaged in developing, manufacturing, and distributing noninvasive medical devices. The company offers products that are typically used to assess and monitor lymphedema and heart failure, as well as to measure the tissue composition and fluid status of the patients. The company also offers a cloud-based digital platform (branded as SOZO) to manage patient data. The company recognises revenue from the stand-alone sale of Legacy Devices and Consumables, the Sale of SOZO Devices, and Software Subscription Services.
Founded
1999
HQ

Employees
77
Website
Financials (LTM)
EV
$12M
Valuation Multiples
Start free trialImpedimed Financials
Impedimed reported last 12-month revenue of $11M and negative EBITDA of ($11M).
In the same LTM period, Impedimed generated ($11M) in EBITDA losses and had net loss of ($15M).
Revenue (LTM)
Impedimed P&L
In the most recent fiscal year, Impedimed reported revenue of $9M and EBITDA of ($12M).
Impedimed is unprofitable as of last fiscal year, with gross margin of 86%, EBITDA margin of (132%), and net margin of (169%).
Financial data powered by Morningstar, Inc.
Impedimed Stock Performance
Impedimed has current market cap of $10M, and enterprise value of $12M.
Market Cap Evolution
Impedimed's stock price is $0.00.
Impedimed share price decreased by 16.1% in the last 30 days, and by 83.0% in the last year.
Impedimed has an EPS (earnings per share) of $-0.01.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $12M | $10M | 0.0% | -16.1% | -60.7% | -83.0% | $-0.01 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialImpedimed Valuation Multiples
Impedimed trades at 1.1x EV/Revenue multiple, and (1.1x) EV/EBITDA.
EV / Revenue (LTM)
Impedimed Financial Valuation Multiples
As of June 15, 2026, Impedimed has market cap of $10M and EV of $12M.
Impedimed has a P/E ratio of (0.7x).
Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified Impedimed Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.


Impedimed Margins & Growth Rates
Impedimed grew revenue by 22% but EBITDA decreased by 6% in the last fiscal year.
In the most recent fiscal year, Impedimed reported gross margin of 86%, EBITDA margin of (132%), and net margin of (169%).
Impedimed Margins
Impedimed Growth Rates
Data powered by FactSet, Inc. and Morningstar, Inc.
Impedimed Operational KPIs
Impedimed's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.3M for the same period.
Impedimed's Rule of 40 is (34%) (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Impedimed's Rule of X is 13% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
Data powered by FactSet, Inc. and Morningstar, Inc.
Impedimed Competitors
Impedimed competitors include Scandinavian ChemoTech, Allurion, Spineguard, Predict, Vidavo, Nestmedic, Conneqt Health, iXensor, BibbInstruments and Lifecare.
Most Impedimed public comparables operate across Health Data & Analytics, Medical Devices, DeepTech and HealthTech.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| Last FY | LTM | 2027E | Last FY | LTM | 2027E | |
| 7.1x | 5.7x | (21.5x) | (34.3x) | |||
| 2.3x | - | (1.2x) | - | |||
| 2.2x | 2.0x | (7.5x) | (12.4x) | |||
| 0.9x | - | 8.4x | - | |||
| 3.8x | - | 10.1x | - | |||
| 39.2x | - | (9.8x) | - | |||
| 4.8x | 5.1x | (1.0x) | - | |||
| 10.9x | - | (7.4x) | - | |||
This data is available for Pro users. Sign up to see all Impedimed competitors and their valuation data. Start Free Trial | ||||||
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout Impedimed
| When was Impedimed founded? | Impedimed was founded in 1999. |
| Where is Impedimed headquartered? | Impedimed is headquartered in United States. |
| How many employees does Impedimed have? | As of today, Impedimed has over 77 employees. |
| Is Impedimed publicly listed? | Yes, Impedimed is a public company listed on Australian Securities Exchange. |
| What is the stock symbol of Impedimed? | Impedimed trades under IPD ticker. |
| When did Impedimed go public? | Impedimed went public in 2007. |
| Who are competitors of Impedimed? | Impedimed main competitors include Scandinavian ChemoTech, Allurion, Spineguard, Predict, Vidavo, Nestmedic, Conneqt Health, iXensor, BibbInstruments, Lifecare. |
| What is the current market cap of Impedimed? | Impedimed's current market cap is $10M. |
| What is the current revenue of Impedimed? | Impedimed's last 12 months revenue is $11M. |
| What is the current revenue growth of Impedimed? | Impedimed revenue growth (NTM/LTM) is 39%. |
| What is the current EV/Revenue multiple of Impedimed? | Current revenue multiple of Impedimed is 1.1x. |
| Is Impedimed profitable? | No, Impedimed is not profitable. |
| What is the current EBITDA of Impedimed? | Impedimed has negative EBITDA and is not profitable. |
| What is Impedimed's EBITDA margin? | Impedimed's last 12 months EBITDA margin is (103%). |
| What is the current EV/EBITDA multiple of Impedimed? | Current EBITDA multiple of Impedimed is (1.1x). |
| What is the current FCF of Impedimed? | Impedimed's last 12 months FCF is ($14M). |
| What is Impedimed's FCF margin? | Impedimed's last 12 months FCF margin is (129%). |
| What is the current EV/FCF multiple of Impedimed? | Current FCF multiple of Impedimed is (0.8x). |
| How many companies Impedimed has acquired to date? | Impedimed hasn't acquired any companies yet (or none have been disclosed publicly). |
| In how many companies Impedimed has invested to date? | Impedimed hasn't invested in any companies yet (or none have been disclosed publicly). |
See public comps similar to Impedimed
Lists including Impedimed
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.